LNG Energy Group Corp. - MCURF STOCK NEWS

MINDCURE (CSE: MCUR, OTCQB: MCURF) has completed the first stage of manufacturing pharmaceutical grade synthetic ibogaine for clinical research. The successful completion includes establishing chemistry and manufacturing processes. The next phase will focus on scaling up production and assessing quality and economic viability for commercial use. MINDCURE aims to provide a sustainable supply of synthetic ibogaine to support clinical trials, addressing addiction and neurological conditions. The company has also granted 10,000 stock options at $0.38 per share as part of its incentive plan.

Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) has appointed Dr. Joel Raskin as Chief Medical Officer, enhancing its leadership in psychedelic therapy. Dr. Raskin, with 20 years in neuroscience drug development, will oversee drug research and commercial strategies aimed at treating migraines, depression, and anxiety. His extensive experience includes leadership roles at Eli Lilly & Co. and positions on scientific review committees. This appointment aligns with MINDCURE's mission to advance effective mental health treatments through scientific research.

Mind Cure Health (CSE: MCUR) (OTCQB: MCURF) has appointed Dr. John Brownstein, Chief Innovation Officer at Boston Children's Hospital, as an Advisor. Dr. Brownstein, renowned for his work in digital health and data management, will contribute to the development of iSTRYM, MINDCURE's psychedelics digital therapeutics platform. His expertise aims to enhance patient data security and optimize treatment protocols. The company also granted 360,000 stock options to employees at varying prices. MINDCURE focuses on improving mental health treatment through innovative technology.

Mind Cure Health has partnered with SOMA Breath to license its 21-day breathwork program and develop custom tracks for psychedelic-assisted therapies. This partnership aims to create a resource for therapists and patients on the iSTRYM platform, enhancing mental health support. SOMA Breath's techniques have shown potential in reducing anxiety and replicating psychedelic experiences. The iSTRYM application is projected to release a beta version in late July 2021, offering users tailored mental health solutions.

Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) announces the appointment of Michael Wolfe as Chief Financial Officer and Larissa Chaikowsky to its Board of Directors. Wolfe brings over 30 years of financial expertise, particularly in capital markets and private equity, from his prior role as CFO at Baylin Technologies. Chaikowsky, currently COO at BMO Wealth Management, offers extensive experience in corporate governance and operational risk. CEO Kelsey Ramsden hailed their appointments as pivotal for advancing MINDCURE's digital therapeutics strategy and capital raising efforts.

MINDCURE has partnered with LUCID to enhance its iSTRYM platform, integrating AI-driven music therapy for psychedelic-assisted treatments. This collaboration aims to customize music experiences based on real-time patient feedback, optimizing therapeutic outcomes. Previous trials have shown LUCID's technology to effectively alleviate anxiety, suggesting potential benefits for patients undergoing psychedelic therapy. The company also granted 610,000 stock options at $0.60 per share as part of its incentive plan. This strategic partnership positions MINDCURE as a leader in personalized mental health solutions.

Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) has appointed Daniel Herrera as Vice President of Growth and Strategic Partnerships. With over 15 years in life sciences and experience in both startups and multinational firms, Herrera's role will focus on driving commercial strategies and establishing crucial partnerships. Prior to this, he led corporate development at Medcolcanna and held significant positions at CannTrust and Eli Lilly. His expertise will bolster MINDCURE’s mission to enhance mental health care solutions.

Mind Cure Health has announced a new partnership with Speak Ai to enhance its iSTRYM platform, which focuses on psychedelic-assisted psychotherapy. This collaboration aims to leverage Speak Ai's advanced AI technology to provide therapists with insights that improve patient outcomes. By integrating audio, video, and text analytics, the partnership will enable structured data analysis, enhancing care protocols. This initiative aligns with Mind Cure's goal of reinventing mental health treatments and improving efficiency in therapy practices.

Mind Cure Health Inc. (CSE: MCUR, OTCQB: MCURF) has announced a strategic equity investment of $350,000 in ATMA Journey Centers Inc., retaining a 13% ownership stake. This investment aligns with a letter of intent from January 2021. CEO Kelsey Ramsden will join ATMA's Board, enhancing collaboration in deploying MINDCURE's iSTRYM technology for psychedelic therapy. This partnership aims to optimize treatment efficacy for ATMA's patients and is expected to drive near-term revenues. MINDCURE also engaged Psychedelic Finance for media support, investing $60,000 for six months.